Across the recent three months, 7 analysts have shared their insights on Liquidia (NASDAQ:LQDA), expressing a variety of opinions spanning from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $52.0, along with a high estimate of $55.00 and a low estimate of $49.00. This current average reflects an increase of 5.2% from the previous average price target of $49.43.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of Liquidia by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Liquidia. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Liquidia compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Liquidia's stock. This examination reveals shifts in analysts' expectations over time.

For valuable insights into Liquidia's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Liquidia analyst ratings.

All You Need to Know About Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Financial Insights: Liquidia

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: Liquidia displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 1121.72%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.5%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Liquidia's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -18.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Liquidia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.32%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Liquidia's debt-to-equity ratio is notably higher than the industry average. With a ratio of 9.03, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Significance of Analyst Ratings Explained

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.